THERAPY WITH CELLS FROM HUMAN PLACENTA AND HEMATOPOIETIC CELLS

(19)

(11)

EP 3 052 109 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.06.2021 Bulletin 2021/25

(45)	Mention of the grant of the patent:
	12.05.2021 Bulletin 2021/19

(21)	Application number: 14850630.6

(22)	Date of filing: 02.10.2014

(51)

International Patent Classification (IPC):

A61K 35/44^(2015.01)
A61P 7/00^(2006.01)
A61P 43/00^(2006.01)
A61K 35/12^(2015.01)
A61P 7/04^(2006.01)
A61P 25/28^(2006.01)
A61P 37/04^(2006.01)

A61P 35/00^(2006.01)
A61P 3/00^(2006.01)
A61K 35/51^(2015.01)
A61K 35/50^(2015.01)
A61P 7/06^(2006.01)
A61P 35/02^(2006.01)
A61P 37/06^(2006.01)

(86)	International application number:
	PCT/US2014/058774

(87)	International publication number:
	WO 2015/051088 (09.04.2015 Gazette 2015/14)

(54)	THERAPY WITH CELLS FROM HUMAN PLACENTA AND HEMATOPOIETIC CELLS THERAPIE MIT ZELLEN AUS MENSCHLICHER PLAZENTA UND HÄMATOPOETISCHEN ZELLEN THÉRAPIE À CELLULES PROVENANT DE PLACENTA HUMAIN ET DES CELLULES HÉMATOPOÏÉTIQUES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME

(30)

Priority:

03.10.2013 US 201361886648 P
11.10.2013 US 201361890057 P

(43)	Date of publication of application:
	10.08.2016 Bulletin 2016/32

(73)	Proprietor: Celularity Inc.
	Florham Park, NJ 07932 (US)

(72)	Inventors:
	GURNEY, Jodi, P. Chicago, IL 60631 (US) ZHANG, Xiaokui Martinsville, NJ 08836 (US) HERB, Stacy Mountain Top, PA 18707 (US) HARIRI, Robert, J. Warren, NJ 07059 (US)

(74)	Representative: Mewburn Ellis LLP
	Aurora Building Counterslip Bristol BS1 6BX Bristol BS1 6BX (GB)

(56)

References cited: :

WO-A2-02/064755
US-A- 5 437 994
US-B2- 8 329 468

WO-A2-2007/089627
US-A- 5 806 529
US-B2- 8 455 250

ARIEN-ZAKAY H ET AL: "Tissue regeneration potential in human umbilical cord blood", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 2, 1 June 2010 (2010-06-01), pages 291-303, XP027277895, ISSN: 1521-6926 [retrieved on 2010-06-01]
LI CHANG DONG ET AL: "MESENCHYMAL STEM CELLS DERIVED FROM HUMAN PLACENTA SUPPRESS ALLOGENEIC UMBILICAL CORD BLOOD LYMPHOCYTE PROLIFERATION", CELL RESEARCH - XIBAO YANJIU, NATURE PUBLISHING GROUP, GB, CN, vol. 15, no. 7, 1 July 2005 (2005-07-01), pages 539-547, XP009080356, ISSN: 1001-0602, DOI: 10.1038/SJ.CR.7290323
SIRCHIA G & REBULLA P: "Placental/umbilical cord blood transplantation", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, vol. 84, no. 8, 1 August 1999 (1999-08-01) , pages 738-747, XP002226904, ISSN: 0390-6078
CHIN T W ET AL: "Enhanced interferon production and lymphokine-activated cytotoxicity of human placental cells", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 113, no. 1, 15 April 1988 (1988-04-15), pages 1-9, XP024003348, ISSN: 0008-8749, DOI: 10.1016/0008-8749(88)90001-9 [retrieved on 1988-04-15]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).